Sargent Investment Group LLC Sells 52,500 Shares of MediWound Ltd. (NASDAQ:MDWD)

Sargent Investment Group LLC reduced its position in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) by 43.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 68,690 shares of the biopharmaceutical company's stock after selling 52,500 shares during the period. Sargent Investment Group LLC owned about 0.64% of MediWound worth $1,066,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its position in MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 1,703 shares during the last quarter. Russell Investments Group Ltd. lifted its position in MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,162 shares during the last quarter. Bank of America Corp DE lifted its position in MediWound by 38.0% in the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock valued at $141,000 after acquiring an additional 2,178 shares during the last quarter. MGO One Seven LLC purchased a new stake in MediWound in the fourth quarter valued at $216,000. Finally, Barclays PLC lifted its position in MediWound by 11.2% in the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock valued at $221,000 after acquiring an additional 1,249 shares during the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Trading Up 1.5%

Shares of NASDAQ MDWD traded up $0.31 during midday trading on Wednesday, reaching $20.80. The company's stock had a trading volume of 47,823 shares, compared to its average volume of 71,267. The company has a 50 day moving average price of $20.28 and a 200 day moving average price of $18.50. MediWound Ltd. has a one year low of $14.14 and a one year high of $22.50. The company has a market cap of $224.79 million, a price-to-earnings ratio of -9.95 and a beta of 0.32.

MediWound (NASDAQ:MDWD - Get Free Report) last released its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.58. The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. During the same period last year, the firm posted ($1.05) earnings per share. Research analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Alliance Global Partners assumed coverage on shares of MediWound in a report on Friday, May 2nd. They issued a "buy" rating and a $25.00 target price for the company. HC Wainwright set a $31.00 target price on shares of MediWound and gave the company a "buy" rating in a report on Thursday, May 22nd. Oppenheimer began coverage on shares of MediWound in a report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 target price for the company. Finally, Wall Street Zen lowered shares of MediWound from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, MediWound currently has a consensus rating of "Moderate Buy" and an average price target of $32.25.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.